Benzonatate 100 Mg Capsule, Liquid Filled
FDA Label NDC 25000-002

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p- (butylamino) benzoate; with a molecular weight of 603.7.

Benzonatate-capsules-description (Benzonatate Capsules Description)

Each Benzonatate Capsule contains Benzonatate, USP 100 mg or 200 mg

Benzonatate Capsules USP also contain: gelatin, glycerin, purified water, sorbitol sorbitan solution. The imprinting ink contains propylene glycol, shellac and titanium dioxide.

FDA approved dissolution test specifications differ from USP.

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

Benzonatate capsules are indicated for the symptomatic relief of cough.

Hypersensitivity to benzonatate or related compounds.

Hypersensitivity 
Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

Psychiatric Effects 
Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs.

Accidental Ingestion and Death in Children 
Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE)

Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush benzonatate capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

Keep benzonatate capsules out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.

Overdosage resulting in death may occur in adults.

Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of benzonatate capsules, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate capsules at one time.

Usage in Pregnancy: Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate is administered to a nursing woman.

Carcinogenesis, mutagenesis, impairment of fertility: Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.

Pediatric Use: Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

Potential Adverse Reactions to benzonatate may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.

GI: constipation; nausea; GI upset.

Dermatologic: pruritus; skin eruptions.

Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.

Deliberate or accidental overdose has resulted in death, particularly in children.

Intentional and unintentional overdose may result in death, particularly in children.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms:

The signs and symptoms of overdose of benzonatate have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.
CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

Treatment:
In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.
Do not use CNS stimulants.

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate Capsules should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

Benzonatate Capsules USP, 100 mg (Light yellow to yellow coloured, transparent to translucent, oval shaped capsule imprinted with '132' in white colour on capsule shell)
Bottle of 30
NDC 25000-002-03

Benzonatate Capsules USP, 100 mg (Light yellow to yellow coloured, transparent to translucent, oval shaped capsule imprinted with '132' in white colour on capsule shell)
Bottle of 100
NDC 25000-002-08

Benzonatate Capsules USP, 100 mg (Light yellow to yellow coloured, transparent to translucent, oval shaped capsule imprinted with '132' in white colour on capsule shell)
Bottle of 500
NDC 25000-002-12


Benzonatate Capsules USP, 200 mg (Light yellow to yellow coloured, transparent to translucent, oval shaped capsule imprinted with '137' in white colour on capsule shell)
Bottle of 30
NDC 25000-003-03


Benzonatate Capsules USP, 200 mg (Light yellow to yellow coloured, transparent to translucent, oval shaped capsule imprinted with '137' in white colour on capsule shell)
Bottle of 100
NDC 25000-003-08


Benzonatate Capsules USP, 200 mg (Light yellow to yellow coloured, transparent to translucent, oval shaped capsule imprinted with '137' in white colour on capsule shell)
Bottle of 500
NDC 25000-003-12

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light.

To report SUSPECTED ADVERSE REACTIONS, contact Marksans Pharma Ltd. at 1-877-290-4008 and/or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for:
Time-Cap Labs, Inc.
7 Michael Avenue, Farmingdale, NY 11735, USA

Manufactured by:
Marksans Pharma Ltd.
Plot No. L-82, L-83, Verna Indl. Estate,
Verna, Goa-403722, India

Rev. 03/26

NDC 25000-002-03
Benzonatate Capsules USP, 100 mg
30 count bottle label 

Benzonatate-capsules-100mg-30s-label (Benzonatate Capsules 100mg 30s Label)

NDC 25000-002-08
Benzonatate Capsules USP, 100 mg
100 count bottle label

Benzonatate-capsules-100mg-100s-label (Benzonatate Capsules 100mg 100s Label)

NDC 25000-002-12
Benzonatate Capsules USP, 100 mg
500 count bottle label

Benzonatate-capsules-100mg-500s-label (Benzonatate Capsules 100mg 500s Label)

NDC 25000-003-03
Benzonatate Capsules USP, 200 mg
30 count bottle label

Benzonatate-capsules-200mg-30s-label (Benzonatate Capsules 200mg 30s Label)

NDC 25000-003-08
Benzonatate Capsules USP, 200 mg
100 count bottle label

Benzonatate-capsules-200mg-100s-label (Benzonatate Capsules 200mg 100s Label)

NDC 25000-003-12
Benzonatate Capsules USP, 200 mg
500 count bottle label

Benzonatate-capsules-200mg-500s-label (Benzonatate Capsules 200mg 500s Label)